Positive Signs As Multiple Insiders Buy Aprea Therapeutics Stock

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in Aprea Therapeutics, Inc.'s (NASDAQ:APRE) case, it's fantastic news for shareholders.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Aprea Therapeutics

The Last 12 Months Of Insider Transactions At Aprea Therapeutics

In fact, the recent purchase by Marc Duey was the biggest purchase of Aprea Therapeutics shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of US$4.40 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Aprea Therapeutics share holders is that insiders were buying at near the current price.

In the last twelve months Aprea Therapeutics insiders were buying shares, but not selling. The average buy price was around US$4.86. These transactions suggest that insiders have considered the current price attractive. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Aprea Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Aprea Therapeutics Insiders Bought Stock Recently

It's good to see that Aprea Therapeutics insiders have made notable investments in the company's shares. Overall, four insiders shelled out US$164k for shares in the company -- and none sold. This could be interpreted as suggesting a positive outlook.

Insider Ownership Of Aprea Therapeutics

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Aprea Therapeutics insiders own about US$2.7m worth of shares (which is 11% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Does This Data Suggest About Aprea Therapeutics Insiders?

It is good to see recent purchasing. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Aprea Therapeutics insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aprea Therapeutics. Every company has risks, and we've spotted 6 warning signs for Aprea Therapeutics (of which 1 shouldn't be ignored!) you should know about.

But note: Aprea Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.